Found 6 matching trials
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
PHASE2This clinical trial is designed to evaluate the effectiveness and collect a...
Location
University of California-San Francisco
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
PHASE1This study is designed to identify the best tolerated doses of Lutathera® a...
Location
Holden Comprehensive Cancer Center
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
N/AThe purpose of this sub-study is to provide expanded access of AZEDRA (Ultr...
Status
Approved For Marketing
Location
University of Iowa
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
PHASE1The purpose of this study is to determine whether iobenguane I 131 is safe ...
Location
New York Presbyterian Hospital-Weill Cornell Medical Center
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
PHASE2RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine ...
Location
Childrens Hospital Los Angeles
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
N/AThis is a compassionate use protocol to allow patients with advanced neurob...
Location
University of California, San Francisco